DAVID POPLACK to Combined Modality Therapy
This is a "connection" page, showing publications DAVID POPLACK has written about Combined Modality Therapy.
Connection Strength
0.136
-
Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
Score: 0.025
-
Advances in the treatment of meningeal cancers. Crit Rev Oncol Hematol. 1995 Aug; 20(1-2):87-98.
Score: 0.024
-
Development of chemotherapy treatment for pediatric brain tumors. Neurol Clin. 1991 May; 9(2):363-73.
Score: 0.018
-
Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: association with attention deficits. Am J Pediatr Hematol Oncol. 1990; 12(2):174-81.
Score: 0.016
-
Acute lymphoblastic leukemia in childhood. Pediatr Clin North Am. 1988 Aug; 35(4):903-32.
Score: 0.015
-
Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985 Jun; 12(2):131-48.
Score: 0.012
-
Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein. Med Pediatr Oncol. 1985; 13(1):4-8.
Score: 0.012
-
Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998 Nov 15; 92(10):3569-77.
Score: 0.008
-
Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8.
Score: 0.005
-
Attentional deficits in long-term survivors of childhood acute lymphoblastic leukemia (ALL). J Clin Neuropsychol. 1984 Aug; 6(3):325-36.
Score: 0.003